Top

Published in:

01-03-2016 | Original Article

Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study

Authors: Tulay Kus, Gokmen Aktas, Mehmet Emin Kalender, Alper Sevinc, Seval Kul, Ali Suner, Esra Ulker, Celaletdin Camci

Published in: Supportive Care in Cancer | Issue 3/2016

Abstract

Purpose

The purpose of this study was to determine whether the presence of diabetes mellitus (DM) influences the incidence and severity of peripheral sensory neuropathy (PSN) in patients using taxane therapy.

Methods

A retrospective single-center analysis was conducted: Patients with PSN at baseline were excluded. The incidence of PSN was evaluated retrospectively in patient subgroups who received taxane arm and taxane-plus-platinum-agents combination arm with or without known DM at baseline.

Results

Three hundred seventy-four patients were enrolled in this study, 81 (21.6 %) of patients had DM at baseline. The incidence of grade 1 PSN (non-DM/DM) in patients receiving taxane-based chemotherapy was 33.4/25.9 % and more than grade 2 PSN (non-DM/DM) was 15/34.6 %. The rate of neuropathy of non-diabetic patients was 48.8 %, while the rate of diabetic patients was 52.8 and 75 % in DM duration below 5 years and above 5 years group, respectively.

Conclusions

This retrospective analysis indicates that taxane-based therapy in DM patients whose disease duration is above 5 years appears to affect the incidence and severity of PSN without known baseline neuropathy. The probability of PSN with taxane-based therapy was similar in DM duration below 5 years and non-DM patients.

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapyinduced peripheral neuropathy. Semin Oncol 33:15–49 6CrossRefPubMed

Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377–387CrossRefPubMed

Hagiwara H, Sunada Y (2004) Mechanism of taxane neurotoxicity. Breast Cancer 11:82–85CrossRefPubMed

Hamid HS, Mervak CM, Münch AE, Robell NJ, Hayes JM, Porzio MT et al (2014) Hyperglycemia- and neuropathy-induced changes in mitochondria within sensory nerves. nn Clin Transl Neurol 1:799–812CrossRef

Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549–1563CrossRefPubMed

Edgardo R, Mary C (2015) Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 75(4):659–70CrossRef

Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259CrossRefPubMed

Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 66:218–228CrossRefPubMed

Peters CM, Jimenez-Andrade JM, Jonas BM, Sevcik MA, Koewler NJ, Ghilardi JR, Wong GY, Manthy PW (2007) Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized bymacrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 203:42–54CrossRefPubMed

10.

Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P et al (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858–1867PubMed

11.

Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P et al (2004) Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 15:1517–1526CrossRefPubMed

12.

Chaudhry V, Chaudhry M, Crawford TO, Simmons-O’Brien E, Griffin JW (2003) Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60:337–340CrossRefPubMed

13.

Miltenburg NC, Boogerd W (2014) Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev 40:872–882CrossRefPubMed

14.

Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M (2013) Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 142:109–118CrossRefPubMed

15.

Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125:767–774CrossRefPubMed

16.

Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubulestabilizing agents. J Clin Oncol 24:1633–1642CrossRefPubMed

17.

Argyriou AA, Polychronopoulos P, Koutras A, Xiros N, Petsas T, Argyriou K, Kalofonos HP, Choroni E (2007) Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care 16:231–237CrossRef

18.

Amir A, Jaipaul S, SatyanR (2014) Pathogenesis of painful diabetic Neuropathy.Pain Res Treat:412041

19.

Partanen J, Niskanen L, Lehtinen J, Mervaale E, Siitonen O, Uusitupa M (1995) Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 33:89–94CrossRef

20.

Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V et al (2012) Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane containing therapy for operable breast cancer. J Clin Oncol 30:3051–3057PubMedCentralCrossRefPubMed

Title: Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study
Authors: Tulay Kus
Gokmen Aktas
Mehmet Emin Kalender
Alper Sevinc
Seval Kul
Ali Suner
Esra Ulker
Celaletdin Camci
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 3/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2898-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes

Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate

Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy

Port catheter versus peripherally inserted central catheter for postoperative chemotherapy in early breast cancer: a retrospective analysis of 448 patients

Interventional options for the management of refractory cancer pain—what is the evidence?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer